Probes List

Please click here to download a PDF containing our F.I.S.H. Probes List, or browse the list below.

TARGET
DISEASE
LOCUS
APPLICATION
IGH/CCDN1
Mantle Cell Lymphoma (MCL)
†(11;14)
To confirm the diagnosis of mantle cell lymphoma.
IGH/BCL2
Follicular Lymphoma (FL)
†(14;18)
To provide additional support to the diagnosis of follicular lymphoma.
IGH
Diffuse Large B-Cell Lymphoma (DLBCL)
14q32
Immunoglobulin heavy chain (IgH) rearrangement can be identified in about 70% of DLBCL cases.
IGH/BCL2
†(14;18)
Found in 15 to 30% of DLBCL.
MYC
Burkitt’s Lymphoma/Leukemia
8q24
To confirm Burkitt lymphoma, including †(8;14), †(2;8) and †(8;22).
TARGET
DISEASE
LOCUS
APPLICATION
BCR/ABL
Acute Lymphocytic Leukemia (ALL)
†(9;22)
Unfavorable prognosis, especially if accompanied by monosomy 7. Detectable in 20-35% of adult and 5% of childhood ALL patients.
PML/RARA
Acute Promyelocytic Leukemia (APL)
†(15;17)
Favorable prognosis, Diagnostic for acute promyelocytic leukemia. Detected in about 5-8% of AML patients. Treatment with alltrans retinoic acid (ATRA) and other chemotherapy agents can induce remission and terminate disseminated intravascular coagulation (DIC).
Chromosome 8
AML with Multilineage Dysplasia
+8
Intermediate prognosis.
TARGET
DISEASE
LOCUS
APPLICATION
IGH/CCND1
Multiple Myeloma (MM)
†(11;14)
Favorable prognosis, compared to other IgH rearrangements. t(11;14) is associated with cyclin D1 overexpression.
TARGET
DISEASE
LOCUS
APPLICATION
BCR/ABL

Chronic Myeloid Leukemia (CML)
†(9;22)
Diagnostic for CML and also seen in a subset of ALL and AML.
Chromosome 8
+8

Associated with accelerated/blast phase of CML.
TARGET
DISEASE
LOCUS
APPLICATION
-5/5q-
5q31

Associated with favorable prognosis. 5q- is found in 10-15% of MDS.
-7/7q
7q31
Unfavorable prognosis.
Chromosome 8
+8
Intermediate prognosis.
20q12
20q-

Favorable prognosis if it is the sole abnormality. A chromosomal 20q deletion is seen in 5% of primary MDS.
p53
17p13

Unfavorable prognosis. Deletion is usually found in transformation to AML.
TARGET
DISEASE
LOCUS
APPLICATION
HER2

Breast Cancer (PathVysion ®) (Vysis)
17q

Unfavorable prognosis. Prognostic for amplification/overexpression of HER2. Stratifies patients for Herceptin® therapy.
Chromosome 3
Bladder Cancer (UroVysion ®)
+3
Detects aneuploidy for chromosomes 3,7,17 and loss of the 9p21 locus as an aid both in initial diagnosis and for monitoring tumor recurrence.
Chromosome 7
+7
Detects aneuploidy for chromosomes 3,7,17 and loss of the 9p21 locus as an aid both in initial diagnosis and for monitoring tumor recurrence.
Chromosome 17
+17
Detects aneuploidy for chromosomes 3,7,17 and loss of the 9p21 locus as an aid both in initial diagnosis and for monitoring tumor recurrence
p16
Detects aneuploidy for chromosomes 3,7,17 and loss of the 9p21 locus as an aid both in initial diagnosis and for monitoring tumor recurrence.
SYT
Synovial Sarcoma
18q1
x;18 translocation is very specific and sensitive for the diagnosis of S.
EWSR
Ewing’s Sarcoma
22q12
Translocation of EWSR/Fli1 is observed in over 85% of Ewing’s sarcomas.
FKHR
Alveolar Rhabdomyosarcoma
11p15.5
Oligodendroglioma
1p36/
1q25
Deletion of either (or both) 1p36 and 19p13 supports the diagnosis of oligodendroglioma and is associated with a better prognosis.
19q13/
19p12
EGFR
Lung Caner, Breast Cancer
7p12
EGFR gene status is related to response to anti-EGFR therapy.
DNA Ploidy
Multiple tumors, and major pregnancy
Multiple Chromosomes
Topoisomerase II Alpha
Breast Cancer
17q21-22
Can predict the response to adriamycin-based chemotherapy.